文章：

嵌合抗原受体T细胞在现代慢性淋巴细胞白血病治疗中的应用

Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment

原文发布日期：15 January 2025

DOI: 10.3390/cancers17020268

类型: Article

开放获取: 是

英文摘要：

Pathway inhibitors targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) have dramatically changed the treatment landscape for both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). However, with increased utilization, a growing number of patients will experience progressive disease on both agents. This subgroup of “double refractory” patients has limited treatment options and poor prognosis. Chimeric antigen receptor (CAR)-T cells have transformed the treatment of relapsed/refractory B-cell malignancies. Although the earliest success of CAR-T cell therapy was in CLL, the clinical application of this modality has lagged until the recent approval of the first CAR-T cell product for CLL. In this review, we describe the current treatment options for upfront and subsequent therapies and the unmet need for novel agents highlighted by the burgeoning role and challenges of CAR-T cell therapy.

摘要翻译： 

靶向布鲁顿酪氨酸激酶（BTK）和B细胞淋巴瘤-2（BCL-2）的信号通路抑制剂已显著改变初治及复发/难治性慢性淋巴细胞白血病（CLL）的治疗格局。然而随着临床应用日益广泛，越来越多患者在接受这两种药物治疗后出现疾病进展。这类"双重难治"患者亚群治疗选择有限且预后不良。嵌合抗原受体（CAR）-T细胞疗法已彻底改变复发/难治性B细胞恶性肿瘤的治疗模式。尽管CAR-T细胞疗法最早在CLL领域取得成功，但其临床应用进展相对滞后，直至近期首个CLL适应症的CAR-T细胞产品获批。本文综述了当前CLL一线及后续治疗方案，并探讨CAR-T细胞疗法新兴作用与挑战所揭示的新型治疗药物的未满足需求。

原文链接：

Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment